Essity Welcomes Anand Chandarana as New Health Unit Leader

Essity Appoints Anand Chandarana as President
Essity, a global leader in hygiene and health solutions, has made a significant move by hiring Anand Chandarana as the new President of its Business Unit Health & Medical. With his extensive experience in the healthcare sector, Chandarana is expected to drive the company's growth and innovation in this critical segment.
Experience and Background of Anand Chandarana
Anand Chandarana has been a vital part of Essity since 2020, serving as the Vice President of Commercial Development in the Health & Medical division. His impressive track record includes over 17 years at Mölnlycke Health Care, where he held various senior roles, illustrating his strong expertise in the medical solutions market.
Anand's Vision for the Future
Chandarana will officially take on his new role effective September 1, 2025. He is set to join the Executive Management Team and will report directly to Ulrika Kolsrud, President and CEO of Essity. Kolsrud expressed confidence in Chandarana’s abilities, emphasizing his comprehensive experience in sales, marketing, and innovation as a key driver for the company’s future success.
Health & Medical Business Unit Overview
The Health & Medical division under Essity specializes in a variety of products designed for incontinence care, wound management, compression therapy, and orthopedics. The unit boasts renowned brands like TENA, Leukoplast, Cutimed, Hydrofera BLUE, JOBST, Delta-Cast, and Actimove, which have established a reputation for excellence and reliability in the healthcare market.
Chandarana's Global Perspective
As a dual citizen of the UK and Sweden, Anand brings a unique international perspective that will be beneficial for the global strategies of Essity's health division. His office will be located in Gothenburg, a central hub for Essity's operations.
Commitment to Growth
Essity is determined to enhance its position in the health and medical sector with Chandarana at the helm. His leadership will harness innovation and capitalize on market opportunities to ensure that Essity remains a frontrunner in providing critical healthcare solutions.
Frequently Asked Questions
Who is Anand Chandarana?
Anand Chandarana is the newly appointed President of Essity's Business Unit Health & Medical, set to begin his role on September 1, 2025.
What experience does Anand Chandarana bring?
He has a solid background with Essity, previously serving as Vice President Commercial Development, and has 17 years of experience at Mölnlycke Health Care.
Which brands are under Essity's Health & Medical unit?
Essity's Health & Medical division includes well-known brands such as TENA, Leukoplast, Cutimed, Hydrofera BLUE, JOBST, Delta-Cast, and Actimove.
Where will Anand Chandarana be based?
Chandarana will work from Essity's office in Gothenburg, Sweden.
What is Essity's focus with this appointment?
Essity aims to leverage Chandarana's expertise to drive growth and innovation in its Health & Medical products.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.